Registry update — unassessed
Evidence-Based Longevity Interventions and Targeted Engagement (E.L.I.T.E.)
Trial registry update: COMPLETED. No results reported in the supplied registry record.
RCTN=31Routine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Oct 13, 2026 · Discovered: Oct 13, 2026 · Assessed: — · Research update
What it does not prove
- The abstract does not report whether either intervention improved the primary outcome (MIC-C change) or how the two arms compared to each other.
- The study was not blinded and had no control arm, so any observed changes cannot be distinguished from placebo or natural variation.
- With 31 participants across two active arms, the study was underpowered to detect clinically meaningful differences; this was explicitly a pilot feasibility study.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- 31
- Duration
- 2 months
- Population
- Community-dwelling adults aged 50 to 80 years without diabetes and with a body-mass index of at least 25 kg/m2
- Primary outcome
- Change from baseline to Week 8 in the Muscular-Immune-Cognitive Composite (MIC-C)
- Effect size
- —
- Significance
- Not reported
- Journal
- Sheba Medical Center
- Published
- Oct 13, 2026
Sources
Primary source
- Sheba Medical Center ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
ELITE, Evidence-Based Longevity Interventions and Targeted Engagement, was a randomized, open-label, two-active-arm Phase IIa pilot conducted at Sheba Medical Center in Ramat Gan, Israel.
The purpose of ELITE was to characterize individual response to multidomain healthy-aging interventions over approximately eight weeks by combining a clinical measure of muscular, immune and cognitive function with frequent digital monitoring between study visits.
The primary outcome was change from baseline to Week 8 in the Muscular-Immune-Cognitive Composite (MIC-C).
Prespecified secondary outcomes included safety, study completion and overall protocol adherence.
ELITE enrolled 31 community-dwelling adults aged 50 to 80 years without diabetes and with a body-mass index of at least 25 kg/m2. Participants were randomized 1:1 to one of two active treatment regimens. Arm A received metformin plus semaglutide, and Arm B received metformin plus empagliflozin. Both groups also received the investigational AgeBiotics products AB-01 and AB-02 as common components of the multidomain intervention.
The protocol-defined intervention was algorithmic polytherapy, integrating a multicomponent pharmacologic and investigational-product regimen with longitudinal digital response monitoring and physician-supervised decision support.
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.